Login to Your Account



Connetics Plans To Pay Roche $123M For Oral Psoriasis Drug

By Randall Osborne


Tuesday, February 10, 2004
Adding a third product to its marketed line of dermatology treatments, Connetics Corp. entered an agreement to buy exclusive U.S. rights to F. Hoffmann-La Roche Ltd.'s marketed oral psoriasis drug, Soriatane, for $123 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription